[CAS NO. 1622006-09-0]  Radioprotectin-1

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1622006-09-0]

Fulfillment
Catalog
AS937384
Brand
Arctom Scientific
CAS
1622006-09-0

DESCRIPTION [1622006-09-0]

Overview

MDL-
Molecular Weight486.92
Molecular FormulaC23H19ClN2O6S
SMILESO=C(O)C1=CC(Cl)=CC=C1S(=O)(NCCCCN(C(C2=CC=CC3=CC=CC4=C23)=O)C4=O)=O

For research use only. We do not sell to patients.

Summary

Radioprotectin-1 is a potent and specific nonlipid agonist of lysophosphatidic acid receptor 2 (LPA 2 ) , with an EC 50 value of 25 nM for murine LPA 2 subtype [1] .


IC50 & Target

EC50: 25 nM (murine LPA 2 subtype) [1]


In Vitro

Radioprotectin-1 is a potent agonist of LPA 2 with an EC 50 of 5 pM and functions as a full agonist at the human ortholog of LPA 2 [1] .
Radioprotectin-1 (0-3 μM; 15 minutes) effectively reduces apoptosis induced by γ-irradiation and the radiomimetic drug Adriamycin in cells that expressed LPA 2 either endogenously or after transfection [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay [1]

Cell Line: MEF cells , IEC-6 cells
Concentration: 0 μM, 0.1 μM, 0.3 μM, 1.0 μM,3 μM
Incubation Time: 15 minutes
Result: Protected cells from apoptosis by γ-irradiation- and the radiomimetic chemotherapeutic Adiamycin.

In Vivo

Radioprotectin-1 is a high-potency specific agonist of the murine LPA 2 GPCR [1] .
Radioprotectin-1 (0.1 mg/kg, 0.3 mg/kg; s.c.; every 12 hours; for 3 days) decreases the mortality of C57BL/6 mice in models of the hematopoietic acute radiation syndromes (HE-ARS) and gastrointestinal acute radiation syndromes (GI-ARS) [1] .
Radioprotectin-1 exerts its radioprotective and radiomitigative action through specific activation of the upregulated LPA 2 GPCR in Lgr5 + stem cells [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 8-10 weeks old C57BL/6 female mice bearing total body irradiation (TBI) [1]
Dosage: 0.1 mg/kg, 0.3 mg/kg
Administration: Subcutaneous injection; every 12 hours; for 3 days
Result: Decreased mortality of C57BL/6 mice in models of the HE-ARS and the GI-ARS.

Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month

Solvent & Solubility

In Vitro:

DMSO : 125 mg/mL ( 256.72 mM ; Need ultrasonic)

H 2 O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.0537 mL 10.2686 mL 20.5373 mL
5 mM 0.4107 mL 2.0537 mL 4.1075 mL
10 mM 0.2054 mL 1.0269 mL 2.0537 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

    Solubility: ≥ 2.08 mg/mL (4.27 mM); Clear solution

  • 2.

    Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (4.27 mM); Clear solution

  • 3.

    Add each solvent one by one: 10% DMSO >> 90% corn oil

    Solubility: ≥ 2.08 mg/mL (4.27 mM); Clear solution

* All of the co-solvents are available by MCE.